{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:12:55Z","timestamp":1795126375841,"version":"4.10.3"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005722","name":"LMU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euros.2026.05.017","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:23:14Z","timestamp":1781310194000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"89","author":[{"given":"Jennifer","family":"Linehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianne","family":"Penny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda C.","family":"Kines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"de los Pinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McQuaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-4028","authenticated-orcid":false,"given":"Sabine D.","family":"Brookman-May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.05.017_b0005","unstructured":"EAU Guidelines Office. EAU Guidelines. Presented at the EAU Annual Congress Madrid 2025. Arnhem, The Netherlands: EAU Guidelines Office;2025."},{"key":"10.1016\/j.euros.2026.05.017_b0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.euo.2025.04.010","article-title":"Towards defining follow-up strategies for patients with primary intermediate-risk non-muscle-invasive bladder cancer","volume":"8","author":"Contieri","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.05.017_b0015","doi-asserted-by":"crossref","DOI":"10.14440\/bladder.2024.0051","article-title":"Tolerability and efficacy of induction bacillus Calmette-Guerin for non-muscle invasive bladder cancer","volume":"12","author":"Patel","year":"2025","journal-title":"Bladder"},{"key":"10.1016\/j.euros.2026.05.017_b0020","article-title":"New treatment options for non-muscle-invasive bladder cancer","volume":"45","author":"Filon","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euros.2026.05.017_b0025","first-page":"693","article-title":"[CD]. Virus-like particle-drug conjugates induce protective, long-lasting adaptive antitumor immunity in the absence of specifically targeted tumor antigens. Cancer","volume":"9","author":"Kines","year":"2021","journal-title":"Immunol Res"},{"key":"10.1016\/j.euros.2026.05.017_b0030","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3390\/v14081656","article-title":"Harnessing human papillomavirus' natural tropism to target tumors","volume":"14","author":"Kines","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.euros.2026.05.017_b0035","unstructured":"UROsource. AU-011 late-breaking abstract at the 40th annual European Association of Urology congress. https:\/\/urosource.uroweb.org\/resource-centres\/EAU25\/263401\/abstract; 2025."},{"key":"10.1016\/j.euros.2026.05.017_b0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.05.017_b0045","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the international bladder cancer group: a multicenter young academic urologists urothelial working group collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.05.017_b0050","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"JNCL Natl Cancer Inst"},{"key":"10.1016\/j.euros.2026.05.017_b0055","doi-asserted-by":"crossref","first-page":"11982","DOI":"10.1073\/pnas.1300136110","article-title":"Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue","volume":"110","author":"Gerdes","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.euros.2026.05.017_b0060","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3390\/ijms24043086","article-title":"Multiplex immunofluorescence: A powerful tool in cancer immunotherapy","volume":"24","author":"Sheng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euros.2026.05.017_b0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/BLC-170120","article-title":"Tertiary lymphoid structures associate with tumour Stage in urothelial bladder cancer","volume":"3","author":"Koti","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euros.2026.05.017_b0070","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.euros.2026.05.017_b0075","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder","volume":"181","author":"Oh","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2026.05.017_b0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/360264a0","article-title":"Lifespan of human lymphocyte subsets defined by CD45 isoforms","volume":"360","author":"Michie","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.euros.2026.05.017_b0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01741603","article-title":"Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin","volume":"33","author":"De Boer","year":"1991","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euros.2026.05.017_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970931","article-title":"CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients","volume":"13","author":"Castellano","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.euros.2026.05.017_b0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev-immunol-101220-032117","article-title":"Tissue immunity in the bladder","volume":"40","author":"Bowyer","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.euros.2026.05.017_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155997","article-title":"Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer","volume":"270","author":"Lima","year":"2025","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.euros.2026.05.017_b0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: A single-arm, open-label, Phase 3 trial (ENVISION)-Label","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2026.05.017_b0110","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the Phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.05.017_b0115","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/2326-6066.CIR-20-0432","article-title":"Insights into tumor-associated tertiary lymphoid structures: novel targets for antitumor immunity and cancer immunotherapy","volume":"8","author":"Rodriguez","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.euros.2026.05.017_b0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euros.2026.05.017_b0125","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1038\/s41598-017-11122-2","article-title":"Tumor-infiltrating CD45RO+ memory T lymphocytes predict favorable clinical outcome in solid tumors","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2026.05.017_b0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11934-025-01314-z","article-title":"The emerging role of B cells and tertiary lymphoid structures in bladder cancer","volume":"27","author":"Penunuri","year":"2025","journal-title":"Curr Urol Rep"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326005173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326005173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:08:16Z","timestamp":1783008496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326005173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S2666168326005173"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.05.017","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}